Navigation Links
Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,,and Capecitabine

and granted priority review of, these data as part of the New Drug Application for ixabepilone. The target action date is in late October. The proposed indications for ixabepilone are as a monotherapy to treat patients with metastatic or locally advanced breast cancer after failure of an anthracycline, a taxane, and capecitabine and in combination with capecitabine to treat patients with metastatic or locally advanced breast cancer after failure of an anthracycline and a taxane. The company also plans to submit these data as part of a registrational dossier in the European Union, and other countries this year.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the application submitted to the FDA will be approved, that an application will be submitted or approved in any other country, or, if approved, that the product will be commercially successful. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a resu
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/28/2015)... de agosto de 2015   Royal Philips ... en el  Congreso de la ESC de 2015 ... y novedosas, entre ellas HeartModel A.I.  , EchoNavigator ... y la tecnología con los protocolos de atención ... tratamientos y permitir atención en el hogar. ...
(Date:8/27/2015)... 27, 2015 DURECT Corporation (Nasdaq: DRRX ... at three upcoming healthcare conferences.  , ... present at the Rodman & Renshaw Investment Conference on ... conference is being held at the St. Regis Hotel ... live audio webcast of the presentation will be available ...
(Date:8/27/2015)... MEETING, Pa. , Aug. 27, 2015  Now ... decommissioning the Da Vinci S™ surgical robot, hospitals with ... replacement plans. They also need to see where they ... procedures on the right patients? Have they adopted best ... robotic surgery program in the future? ECRI ...
Breaking Medicine Technology:Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3
... Rcadia Medical Imaging has achieved proof-of-concept with the first ... a coronary CT angiography (cCTA) study. This technology, the ... scoring, has the potential to eliminate the need for ... costs  and decrease patient radiation exposure. This work in ...
... The Renal Therapies Division of B. ... of the Plasmat™ Futura System for H.E.L.P. ®   ... H.E.L.P. ® therapy provides a more easy-to-use system ... patients with severe hypercholesterolemia. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) ...
Cached Medicine Technology:Rcadia's Fully Automatic Calcium Score Assessment from Coronary CTA Shows Potential to Eliminate Need for Separate Scan 2B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System 2
(Date:8/28/2015)... ... 28, 2015 , ... “ Frequentz ” was featured on NewsWatch as part ... on the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch ... allows businesses to track product movement from beginning to end. , Businesses benefit greatly ...
(Date:8/28/2015)... ... August 28, 2015 , ... Drugs and ... James Strawbridge, gives a new approach on solutions in his new book ":Unraveling ... employer and employees getting together for meaningful group meetings. "This would educate the ...
(Date:8/28/2015)... TN (PRWEB) , ... August 28, 2015 , ... ... recipients of the Veterans Award, honoring military veterans leading in business. Mr. ... honorees. , The inaugural Nashville Business Journal's 2015 Veterans Awards will ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., ... resulting in shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and ... the University of Illinois, and then went on to earn his title of Doctor ...
(Date:8/28/2015)... ... , ... The Quatela Center for Plastic Surgery is excited to bring patients ... approved by the Food and Drug Administration to eliminate submental fat, also known as ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     ...
Breaking Medicine News(10 mins):Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... ... that help survivors of stroke and other forms of traumatic brain injury to improve mobility, ... stroke rehabilitation, the Tailwind. (Advance for Physical Therapy and Rehab Medicine, vol. 20, issue 20, ... ...
... ... special woman who has everything? Why stem cells, of course! Celebrity Beauty Engineer® and ... to look and feel their best! , ... (PRWEB) December 16, 2009 -- The holidays are rapidly approaching and what kind ...
... new electrophoretic method for detecting MIRCERA and other erythropoietins ... has specifically enhanced sensitivity for MIRCERA, but does not ... EPOs. Details of this study, funded by a ... the latest issue of Drug Testing and Analysis ...
... , Consumer Watchdog Calls For Preserving State Authority, ... WASHINGTON, Dec. 15 Consumer Watchdog condemned the removal of the ... from the U.S. Senate health reform bill. But the group said ... greatly weakened bill to prevent ceding the entire health care system ...
... , SUNNYVALE, Calif., Dec. 15 Palo Alto ... University has deployed its PA-4000 Series next-generation firewalls for ... enhanced visibility and control over applications such as peer-to-peer ... university with eight facilities on five campuses. The university ...
... Dec. 15 Our Lady of Lourdes Health Care Services ... agreed to pay the United States $7.95 million to resolve ... today. The two hospitals are Our Lady of Lourdes Medical ... Burlington County (LMC) in Willingboro, N.J. , LMC is ...
Cached Medicine News:Health News:New Tailwind Device Improves Arm Function in Stroke Survivors with Paralysis 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2Health News:Researchers discover novel method for detecting MIRCERA 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2
Demineralized Freeze-dried Bone Allograft (DFDBA) processed from cortical bone. Demineralized cortical powder is free of all soft tissue....
Dedicated ENT electromagnetic surgical navigation system. Value priced for comunity hospitals and surgical centers....
... The Summit SI Spinal Fixation ... for rigid posterior fixation of ... spine. The simplicity and versatility ... optimize the construct based on ...
...
Medicine Products: